Anika Therapeutics — Third Quarter 2026 Earnings Summary

Anika Therapeutics reported third-quarter 2026 total revenue of $30.6 million, representing a 10% year-over-year increase driven by 17% growth in the Commercial Channel and 5% growth in the OEM Channel. The company raised its full-year 2026 total revenue guidance to a range of 6% to 10% and increased its adjusted EBITDA margin guidance to 15% to 17%. Key operational highlights include a new 10-year partnership with Boehringer Ingelheim for Hyvisc distribution, the reintroduction of the Hyalomatrix wound product, and the completion of enrollment for the Cingal bioequivalence study. Despite an FDA non-approvable determination for the Hyalofast PMA application, the company continues to assess regulatory pathways while maintaining strong performance in its Integrity and international viscosupplement segments.